Overview

Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Amlodipine
Amlodipine, atorvastatin drug combination
Atorvastatin
Atorvastatin Calcium